Baird analyst David Rescott has initiated coverage on Haemonetics (HAE, Financial) with an "Outperform" rating. This new coverage comes with a price target set at $87.00 USD. The announcement was made on June 26, 2025.
Haemonetics (HAE, Financial), listed on the NYSE, did not have any prior rating or price target from Baird. This initiation marks a significant move for the company's stock, with the analyst expressing a positive outlook.
Investors may find this initiation noteworthy as it presents an opportunity to consider the analyst's expectations for Haemonetics (HAE, Financial). The "Outperform" rating suggests that Baird anticipates the stock will perform better than the overall market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Haemonetics Corp (HAE, Financial) is $91.78 with a high estimate of $108.00 and a low estimate of $68.00. The average target implies an upside of 25.04% from the current price of $73.40. More detailed estimate data can be found on the Haemonetics Corp (HAE) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Haemonetics Corp's (HAE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Haemonetics Corp (HAE, Financial) in one year is $94.08, suggesting a upside of 28.17% from the current price of $73.4. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Haemonetics Corp (HAE) Summary page.
